Faes Farma SA
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. The company also engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal… Read more
Faes Farma SA (FAE) - Total Assets
Latest total assets as of December 2025: €1.34 Billion EUR
Based on the latest financial reports, Faes Farma SA (FAE) holds total assets worth €1.34 Billion EUR as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Faes Farma SA - Total Assets Trend (2000–2025)
This chart illustrates how Faes Farma SA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Faes Farma SA - Asset Composition Analysis
Current Asset Composition (December 2025)
Faes Farma SA's total assets of €1.34 Billion consist of 36.0% current assets and 64.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.7% |
| Accounts Receivable | €167.30 Million | 12.5% |
| Inventory | €185.01 Million | 13.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €199.40 Million | 14.9% |
| Goodwill | €258.48 Million | 19.3% |
Asset Composition Trend (2000–2025)
This chart illustrates how Faes Farma SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Faes Farma SA's current assets represent 36.0% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 8.7% of total assets in 2025, up from 2.5% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 26.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 19.3% of total assets.
Faes Farma SA Competitors by Total Assets
Key competitors of Faes Farma SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Faes Farma SA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Faes Farma SA generates 0.45x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Faes Farma SA generates $5.93 in net profit.
Faes Farma SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.61 | 3.23 | 3.42 |
| Quick Ratio | 1.61 | 1.85 | 2.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €297.52 Million | € 230.27 Million | € 205.32 Million |
Faes Farma SA - Advanced Valuation Insights
This section examines the relationship between Faes Farma SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.98 |
| Latest Market Cap to Assets Ratio | 0.79 |
| Asset Growth Rate (YoY) | 57.3% |
| Total Assets | €1.34 Billion |
| Market Capitalization | $1.05 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Faes Farma SA's assets below their book value (0.79 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Faes Farma SA's assets grew by 57.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Faes Farma SA (2000–2025)
The table below shows the annual total assets of Faes Farma SA from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.34 Billion | +57.30% |
| 2024-12-31 | €853.08 Million | +9.93% |
| 2023-12-31 | €776.03 Million | +6.94% |
| 2022-12-31 | €725.67 Million | +13.07% |
| 2021-12-31 | €641.76 Million | +13.76% |
| 2020-12-31 | €564.15 Million | +14.28% |
| 2019-12-31 | €493.67 Million | +2.68% |
| 2018-12-31 | €480.80 Million | +11.75% |
| 2017-12-31 | €430.24 Million | +29.89% |
| 2016-12-31 | €331.22 Million | +13.95% |
| 2015-12-31 | €290.68 Million | +8.77% |
| 2014-12-31 | €267.23 Million | -6.29% |
| 2013-12-31 | €285.16 Million | -0.59% |
| 2012-12-31 | €286.84 Million | -1.47% |
| 2011-12-31 | €291.12 Million | -2.01% |
| 2010-12-31 | €297.10 Million | +25.91% |
| 2009-12-31 | €235.97 Million | -14.20% |
| 2008-12-31 | €275.01 Million | +0.95% |
| 2007-12-31 | €272.43 Million | +17.21% |
| 2006-12-31 | €232.43 Million | +7.59% |
| 2005-12-31 | €216.04 Million | +8.41% |
| 2004-12-31 | €199.29 Million | +0.64% |
| 2003-12-31 | €198.01 Million | +11.93% |
| 2002-12-31 | €176.91 Million | -99.28% |
| 2001-12-31 | €24.57 Billion | +1.51% |
| 2000-12-31 | €24.21 Billion | -- |